Cancer is generally a huge expanse of never-ending suck, but I got some good news today as I wait for treatment --
My latest ctDNA blood test showed "undetectable levels of cancer DNA". This is, to put it mildly, HUGE.
My latest ctDNA blood test showed "undetectable levels of cancer DNA". This is, to put it mildly, HUGE.
February 18, 2026 at 2:11 PM
Cancer is generally a huge expanse of never-ending suck, but I got some good news today as I wait for treatment --
My latest ctDNA blood test showed "undetectable levels of cancer DNA". This is, to put it mildly, HUGE.
My latest ctDNA blood test showed "undetectable levels of cancer DNA". This is, to put it mildly, HUGE.
Matt Galsky and ctDNA biomarker discovery. @dyrskjot.bsky.social #TOMBOLA.
December 3, 2024 at 8:58 PM
Matt Galsky and ctDNA biomarker discovery. @dyrskjot.bsky.social #TOMBOLA.
Immagina di poter scovare un tumore prima che compaia una massa visibile o che insorgano i primi sintomi. Non è fantascienza, ma la promessa delle biopsie liquide e del sequenziamento del DNA tumorale circolante (ctDNA). Facciamo chiarezza con un thread.
September 21, 2026 at 7:50 PM
Immagina di poter scovare un tumore prima che compaia una massa visibile o che insorgano i primi sintomi. Non è fantascienza, ma la promessa delle biopsie liquide e del sequenziamento del DNA tumorale circolante (ctDNA). Facciamo chiarezza con un thread.
🧬 Early Lung Cancer Breakthrough
A new tool detects ctDNA in 81% of patients with early lung adenocarcinoma, improving risk prediction and survival outcomes. This could transform cancer care by identifying aggressive cases earlier.
🔗 www.nature.com/articles/s41...
#Cancer #SciComm 🧪
A new tool detects ctDNA in 81% of patients with early lung adenocarcinoma, improving risk prediction and survival outcomes. This could transform cancer care by identifying aggressive cases earlier.
🔗 www.nature.com/articles/s41...
#Cancer #SciComm 🧪
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma - Nature Medicine
In the TRACERx cohort of 171 patients with lung cancer, the ultrasensitive detection of ctDNA improves preoperative patient stratification, also in early-stage disease.
www.nature.com
January 14, 2025 at 5:31 PM
🧬 Early Lung Cancer Breakthrough
A new tool detects ctDNA in 81% of patients with early lung adenocarcinoma, improving risk prediction and survival outcomes. This could transform cancer care by identifying aggressive cases earlier.
🔗 www.nature.com/articles/s41...
#Cancer #SciComm 🧪
A new tool detects ctDNA in 81% of patients with early lung adenocarcinoma, improving risk prediction and survival outcomes. This could transform cancer care by identifying aggressive cases earlier.
🔗 www.nature.com/articles/s41...
#Cancer #SciComm 🧪
*** PERSONAL NEWS ***
My first post-surgical TEMPUS ctdna blood test came back negative. No detectable levels of cancer DNA in my body.
I was scheduled to have a CT and start another 12-cycle chemo course tomorrow if it were positive.
But it's not. All cancelled. Next test: 3 months.
My first post-surgical TEMPUS ctdna blood test came back negative. No detectable levels of cancer DNA in my body.
I was scheduled to have a CT and start another 12-cycle chemo course tomorrow if it were positive.
But it's not. All cancelled. Next test: 3 months.
August 12, 2025 at 7:15 PM
*** PERSONAL NEWS ***
My first post-surgical TEMPUS ctdna blood test came back negative. No detectable levels of cancer DNA in my body.
I was scheduled to have a CT and start another 12-cycle chemo course tomorrow if it were positive.
But it's not. All cancelled. Next test: 3 months.
My first post-surgical TEMPUS ctdna blood test came back negative. No detectable levels of cancer DNA in my body.
I was scheduled to have a CT and start another 12-cycle chemo course tomorrow if it were positive.
But it's not. All cancelled. Next test: 3 months.
🎥 WATCH: Alexander N. Shoushtari, MD, of @mskcancercenter.bsky.social, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma. #melsm #oncology
Full video ➡️: www.onclive.com/view/dr-shou...
Full video ➡️: www.onclive.com/view/dr-shou...
Dr Shoushtari on the Promise and Current Limitations of ctDNA Monitoring in Uveal Melanoma | OncLive
Alexander N. Shoushtari, MD, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma.
www.onclive.com
September 29, 2026 at 10:10 PM
🎥 WATCH: Alexander N. Shoushtari, MD, of @mskcancercenter.bsky.social, discusses the current role, benefits, and limitations of monitoring ctDNA in metastatic uveal melanoma. #melsm #oncology
Full video ➡️: www.onclive.com/view/dr-shou...
Full video ➡️: www.onclive.com/view/dr-shou...
High ctDNA tumor fraction boosts confidence in driver-negative reports, while low ctDNA suggests need for confirmatory tissue testing.
#LiquidBiopsy #Oncology #PrecisionMedicine #ISLB24
@christianrolfo.bsky.social @oncoalert.bsky.social
#LiquidBiopsy #Oncology #PrecisionMedicine #ISLB24
@christianrolfo.bsky.social @oncoalert.bsky.social
November 24, 2024 at 7:59 PM
High ctDNA tumor fraction boosts confidence in driver-negative reports, while low ctDNA suggests need for confirmatory tissue testing.
#LiquidBiopsy #Oncology #PrecisionMedicine #ISLB24
@christianrolfo.bsky.social @oncoalert.bsky.social
#LiquidBiopsy #Oncology #PrecisionMedicine #ISLB24
@christianrolfo.bsky.social @oncoalert.bsky.social
In some positive news, my cTDNA test came back clean. So no sign of tumor DNA circulating in my blood right now!
March 3, 2026 at 2:38 AM
In some positive news, my cTDNA test came back clean. So no sign of tumor DNA circulating in my blood right now!
Nature research paper: Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
go.nature.com/4blaovQ
go.nature.com/4blaovQ
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma - Nature
A clinical trial testing whether monitoring ctDNA clearance during treatment for nasopharyngeal cancer could be used to inform decisions about an individual’s subsequent therapeutic programme shows promising results.
go.nature.com
March 12, 2026 at 8:56 AM
Nature research paper: Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
go.nature.com/4blaovQ
go.nature.com/4blaovQ
An insightful session on 'Panning for Gold: The Role of ctDNA as a Biomarker for Bladder Cancer'! Thank you to our expert presenters for shedding light on the potential of ctDNA in advancing diagnosis and treatment. #GU25
February 14, 2025 at 11:35 PM
An insightful session on 'Panning for Gold: The Role of ctDNA as a Biomarker for Bladder Cancer'! Thank you to our expert presenters for shedding light on the potential of ctDNA in advancing diagnosis and treatment. #GU25
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 3:12 PM
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
So long road ahead still, but the news (PET plus earlier negative ctDNA blood test) is excellent.
I'm focusing on the "excellent" part.
I'm focusing on the "excellent" part.
March 4, 2026 at 7:43 PM
So long road ahead still, but the news (PET plus earlier negative ctDNA blood test) is excellent.
I'm focusing on the "excellent" part.
I'm focusing on the "excellent" part.
Sandi Deans in delivering a 14 day genomics service, and the impact of the ctDNA pilots and roll out in potential time saving. CtDNA now pending addition to the Directory @BTOG25
March 4, 2025 at 9:18 AM
Sandi Deans in delivering a 14 day genomics service, and the impact of the ctDNA pilots and roll out in potential time saving. CtDNA now pending addition to the Directory @BTOG25
A practical guide for ctDNA testing in #breastcancer ascopubs.org/doi/10.1200/... @ethicsdoctorp.bsky.social @oncoalert.bsky.social @oncbrothers.bsky.social
November 24, 2024 at 7:53 PM
A practical guide for ctDNA testing in #breastcancer ascopubs.org/doi/10.1200/... @ethicsdoctorp.bsky.social @oncoalert.bsky.social @oncbrothers.bsky.social
Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer
Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - OncoDaily
Yüksel Ürün: Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve / Amado J Zurita, Ana M. Aparicio, Ankara University School of Medicine, cancer,
oncodaily.com
May 5, 2025 at 4:59 PM
Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer
@yukselurun.bsky.social
oncodaily.com/science/yuks...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer
ctDNA and locoregional gastroesophageal cancer by Eric Michael Lander et al. - Erman Akkus
oncodaily.com/insight/erma...
@ermanakkus.bsky.social
#Cancer #GastroesophagealCancer #OncoDaily #Oncology
#Medicine #Health
oncodaily.com/insight/erma...
@ermanakkus.bsky.social
#Cancer #GastroesophagealCancer #OncoDaily #Oncology
#Medicine #Health
Erman Akkus: ctDNA and locoregional gastroesophageal cancer by Eric Michael Lander et al. - OncoDaily
Erman Akkus: ctDNA and locoregional gastroesophageal cancer by Eric Michael Lander et al. / Brandon Huffman, cancer, Eric Michael Lander, Erman Akkus,
oncodaily.com
December 10, 2024 at 6:04 PM
ctDNA and locoregional gastroesophageal cancer by Eric Michael Lander et al. - Erman Akkus
oncodaily.com/insight/erma...
@ermanakkus.bsky.social
#Cancer #GastroesophagealCancer #OncoDaily #Oncology
#Medicine #Health
oncodaily.com/insight/erma...
@ermanakkus.bsky.social
#Cancer #GastroesophagealCancer #OncoDaily #Oncology
#Medicine #Health
#ctDNA Assay Shows High Specificity for Post-Transplant #LiverCancer Recurrence: www.cancernetwork.com/view/ctdna-a...
ctDNA Assay Shows High Specificity for Post-Transplant Liver Cancer Recurrence | CancerNetwork
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
www.cancernetwork.com
September 29, 2026 at 12:05 PM
#ctDNA Assay Shows High Specificity for Post-Transplant #LiverCancer Recurrence: www.cancernetwork.com/view/ctdna-a...
The Dawson Lab has finally landed at #bluesky!
We can't wait to chat to you about #ctDNA and #cancerepigenetics!
Happy to be here 🎉
We can't wait to chat to you about #ctDNA and #cancerepigenetics!
Happy to be here 🎉
December 10, 2024 at 1:01 AM
The Dawson Lab has finally landed at #bluesky!
We can't wait to chat to you about #ctDNA and #cancerepigenetics!
Happy to be here 🎉
We can't wait to chat to you about #ctDNA and #cancerepigenetics!
Happy to be here 🎉
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
Matt Krebs on NHS England ctDNA pilot
To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped
How do we (safely) do this?
❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed
❇️ Non-informative ctDNA: still need tissue NGS
❗️Guidelines coming ❗️
To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped
How do we (safely) do this?
❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed
❇️ Non-informative ctDNA: still need tissue NGS
❗️Guidelines coming ❗️
March 4, 2025 at 9:31 AM
Matt Krebs on NHS England ctDNA pilot
To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped
How do we (safely) do this?
❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed
❇️ Non-informative ctDNA: still need tissue NGS
❗️Guidelines coming ❗️
To make ctDNA cost effective, tissue NGS testing in some patients needs to be stopped
How do we (safely) do this?
❇️ Actionable Tier 1 mutation present ➡️ no tissue NGS confirmation needed
❇️ Non-informative ctDNA: still need tissue NGS
❗️Guidelines coming ❗️
Questo secondo metodo serve a monitorare la cosiddetta Malattia Residua Minima (MRD). Se il ctDNA specifico di quel tumore riappare nel sangue, significa che ci sono ancora cellule in circolo. Lo scopo? Anticipare e prevedere una recidiva con largo anticipo.
September 21, 2026 at 7:51 PM
Questo secondo metodo serve a monitorare la cosiddetta Malattia Residua Minima (MRD). Se il ctDNA specifico di quel tumore riappare nel sangue, significa che ci sono ancora cellule in circolo. Lo scopo? Anticipare e prevedere una recidiva con largo anticipo.
Interesting planned study at @fredhutch.bsky.social using ctDNA for risk adapted therapy in #Hodgkin lymphoma #ash24
December 7, 2024 at 5:55 PM
Interesting planned study at @fredhutch.bsky.social using ctDNA for risk adapted therapy in #Hodgkin lymphoma #ash24
ctDNA was identified as a significant prognostic marker in stage III colon cancer, enriching outcomes for ctDNA-negative patients.
by Taieb J, Souglakos J (...) Laurent-Puig P et 19 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00648
by Taieb J, Souglakos J (...) Laurent-Puig P et 19 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00648
February 13, 2025 at 8:33 AM
ctDNA was identified as a significant prognostic marker in stage III colon cancer, enriching outcomes for ctDNA-negative patients.
by Taieb J, Souglakos J (...) Laurent-Puig P et 19 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00648
by Taieb J, Souglakos J (...) Laurent-Puig P et 19 al. in J Clin Oncol #MedSky
📖 read the article: https://ascopubs.org/doi/10.1200/JCO.24.00648
Brilliant presentation by @christianrolfo.bsky.social from OSUCCC on ctDNA fragmentation in solid tumors!
🔑 message
ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients!
@umbertomalapelle1
@stoverlab.bsky.social
🔑 message
ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients!
@umbertomalapelle1
@stoverlab.bsky.social
November 23, 2024 at 5:47 PM
Brilliant presentation by @christianrolfo.bsky.social from OSUCCC on ctDNA fragmentation in solid tumors!
🔑 message
ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients!
@umbertomalapelle1
@stoverlab.bsky.social
🔑 message
ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients!
@umbertomalapelle1
@stoverlab.bsky.social
The NCCN now recognizes ctDNA as a high-risk factor for recurrence in colon/rectal cancer and as a tool in Merkel cell carcinoma. While promising, routine use outside trials isn’t recommended yet. ctDNA’s role in personalized care is evolving! 🧬✨ #ColonCancer #Oncology #Medsky #Research
NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines
The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.
www.onclive.com
February 12, 2025 at 6:01 PM
The NCCN now recognizes ctDNA as a high-risk factor for recurrence in colon/rectal cancer and as a tool in Merkel cell carcinoma. While promising, routine use outside trials isn’t recommended yet. ctDNA’s role in personalized care is evolving! 🧬✨ #ColonCancer #Oncology #Medsky #Research